KRAS and non-small cell lung carcinoma: To study if KRAS mutation can affect the responsiveness of each NSCLC cell line to erlotinib, an EGFR TKI, we divided five NSCLC cell lines of different genetic backgrounds (Supplementary Table 1) into two groups according to their KRAS mutation status.